香港股市 已收市

IQV Dec 2024 300.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
2.00000.0000 (0.00%)
收市:02:35PM EDT
全螢幕
前收市價2.0000
開市2.0000
買盤0.9500
賣出價1.4000
拍板300.00
到期日2024-12-20
今日波幅2.0000 - 2.0000
合同範圍
成交量1
未平倉合約25
  • Zacks

    IQVIA (IQV) Announces Launch of Trial Technology Platform

    IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.

  • Reuters

    Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows

    As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.

  • Zacks

    Here's Why You Should Hold on to IQVIA (IQV) Stock for Now

    IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.